The ALK inhibitor lorlatinib attenuates lipopolysaccharide-induced neuroinflammation by inhibiting microglial activation and preserving blood-brain barrier integrity. (PubMed, Int Immunopharmacol) - Oct 2, 2026 - "Similar anti-inflammatory effects were observed following ALK knockdown and treatment with another ALK inhibitor, ceritinib (CER), thereby supporting the involvement of ALK-dependent mechanisms. In addition, LOR preserved blood-brain barrier (BBB) integrity, as indicated by reduced Evans blue extravasation, immunoglobulin G (IgG) leakage, and restoration of tight junction (TJ) proteins. Overall, these findings identify ALK-STING signaling as a key regulator of neuroinflammation and suggest that LOR may represent a potential therapeutic agent for neuroinflammatory and neurodegenerative diseases."
Journal • CNS Disorders • Inflammation • Oncology • ALK • STING
|
|
Do-Yeon Kim; Hee-Sun Kim; Jin-Sun Park; Jung-Eun Park; Seong-Eun Kim; Yea-Hyun Leem
|